Cargando…
Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
BACKGROUND: Stenotrophomonas maltophilia is a gram-negative, opportunistic infection that is usually hospital-acquired and associated with high morbidity and mortality. The reported increase in S. maltophilia infections is presumed to be due to an increase in the population at risk. METHODS: We retr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988836/ https://www.ncbi.nlm.nih.gov/pubmed/32016126 http://dx.doi.org/10.1093/ofid/ofaa008 |
_version_ | 1783492324521672704 |
---|---|
author | Hamdi, Ahmed M Fida, Madiha Abu Saleh, Omar M Beam, Elena |
author_facet | Hamdi, Ahmed M Fida, Madiha Abu Saleh, Omar M Beam, Elena |
author_sort | Hamdi, Ahmed M |
collection | PubMed |
description | BACKGROUND: Stenotrophomonas maltophilia is a gram-negative, opportunistic infection that is usually hospital-acquired and associated with high morbidity and mortality. The reported increase in S. maltophilia infections is presumed to be due to an increase in the population at risk. METHODS: We retrospectively reviewed 10-year data for S. maltophilia bacteremia in hospitalized adults at our institution to determine the population at risk, sources of infection, common complications, antimicrobial susceptibility profiles, and clinical outcome trends over the past decade. RESULTS: Among the 98 patients analyzed, the most common source of infection was catheter-related (62, 63.3%). Most isolates (61, 65%) were resistant to ceftazidime; fewer were resistant to trimethoprim-sulfamethoxazole (TMP-SMX; 2, 2.1%) and levofloxacin (22, 23.4%). All-cause in-hospital mortality was 29.6% (29 patients). The highest mortality, 53.8%, was observed in pulmonary sources of bacteremia. CONCLUSIONS: Although TMP-SMX continues to have reliable activity in our cohort, we noted resistance to TMP-SMX in patients with recent TMP-SMX exposure, including a case with developing resistance to TMP-SMX while on therapy. |
format | Online Article Text |
id | pubmed-6988836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-69888362020-02-03 Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience Hamdi, Ahmed M Fida, Madiha Abu Saleh, Omar M Beam, Elena Open Forum Infect Dis Major Article BACKGROUND: Stenotrophomonas maltophilia is a gram-negative, opportunistic infection that is usually hospital-acquired and associated with high morbidity and mortality. The reported increase in S. maltophilia infections is presumed to be due to an increase in the population at risk. METHODS: We retrospectively reviewed 10-year data for S. maltophilia bacteremia in hospitalized adults at our institution to determine the population at risk, sources of infection, common complications, antimicrobial susceptibility profiles, and clinical outcome trends over the past decade. RESULTS: Among the 98 patients analyzed, the most common source of infection was catheter-related (62, 63.3%). Most isolates (61, 65%) were resistant to ceftazidime; fewer were resistant to trimethoprim-sulfamethoxazole (TMP-SMX; 2, 2.1%) and levofloxacin (22, 23.4%). All-cause in-hospital mortality was 29.6% (29 patients). The highest mortality, 53.8%, was observed in pulmonary sources of bacteremia. CONCLUSIONS: Although TMP-SMX continues to have reliable activity in our cohort, we noted resistance to TMP-SMX in patients with recent TMP-SMX exposure, including a case with developing resistance to TMP-SMX while on therapy. Oxford University Press 2020-01-19 /pmc/articles/PMC6988836/ /pubmed/32016126 http://dx.doi.org/10.1093/ofid/ofaa008 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Hamdi, Ahmed M Fida, Madiha Abu Saleh, Omar M Beam, Elena Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience |
title |
Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience |
title_full |
Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience |
title_fullStr |
Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience |
title_full_unstemmed |
Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience |
title_short |
Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience |
title_sort | stenotrophomonas bacteremia antibiotic susceptibility and prognostic determinants: mayo clinic 10-year experience |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988836/ https://www.ncbi.nlm.nih.gov/pubmed/32016126 http://dx.doi.org/10.1093/ofid/ofaa008 |
work_keys_str_mv | AT hamdiahmedm stenotrophomonasbacteremiaantibioticsusceptibilityandprognosticdeterminantsmayoclinic10yearexperience AT fidamadiha stenotrophomonasbacteremiaantibioticsusceptibilityandprognosticdeterminantsmayoclinic10yearexperience AT abusalehomarm stenotrophomonasbacteremiaantibioticsusceptibilityandprognosticdeterminantsmayoclinic10yearexperience AT beamelena stenotrophomonasbacteremiaantibioticsusceptibilityandprognosticdeterminantsmayoclinic10yearexperience |